BIOGEN INC. DL -,0005/ US09062X1037 /
2024-04-17 8:21:07 PM | Chg. -2.85 | Volume | Bid8:57:26 PM | Ask8:57:26 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
181.25EUR | -1.55% | 0 Turnover: 0.00 |
-Bid Size: - | -Ask Size: - | 26.17 bill.EUR | - | - |
GlobeNewswire
03-06
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) i...
GlobeNewswire
03-04
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (...
GlobeNewswire
02-23
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positiv...
GlobeNewswire
02-12
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Tr...
GlobeNewswire
02-08
Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
GlobeNewswire
2023-12-19
Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European C...
GlobeNewswire
2023-12-15
CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Fri...
GlobeNewswire
2023-12-14
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is...
GlobeNewswire
2023-10-25
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study ...
GlobeNewswire
2023-10-25
New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise f...
GlobeNewswire
2023-10-19
Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting
GlobeNewswire
2023-09-29
FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®
GlobeNewswire
2023-09-25
LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan